来自Mesua ferrea L. 叶片的多的α-葡萄糖酶抑制活性
Dong-Dong Zhang1,2,3, Yue-Hu Wang1, Aussara Panya2
1Key Laboratory of Economic Plants and Biotechnology, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China.
Chemistry & biodiversity
|January 24, 2025
概括
梅苏亚铁叶含有抑制阿尔法-葡萄糖酶的化合物,这是与糖尿病有关的酶. 两种化合物表现出强烈的活性,表明了新的糖尿病治疗的潜力.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- Mesua ferrea L. 是一种用于糖尿病的传统药物.
- 阿尔法-葡萄糖酶抑制剂对于管理2型糖尿病至关重要.
研究的目的:
- 从Mesua ferrea叶子中分离和识别具有α-葡萄糖酶抑制活性的生物活性化合物.
- 评估这些化合物作为新型抗糖尿病药物的潜力.
主要方法:
- 在生物试验指导下分化Mesua ferrea叶子提取物.
- 八种多的分离和结构阐明 (六种库马林,两种黄).
- 在3T3-L1脂肪细胞中进行体外α-葡萄糖酶抑制试验和葡萄糖吸收研究.
主要成果:
- 五个孤立的化合物 (1,2,4,6,8) 显示出显著的α-葡萄糖酶抑制 (IC50:1.8142.97μM).
- 奎尔塞丁3-O-(3′′,4′′-di-E-p-coumaroyl) -α-l-rhamnoside (8) 和哺乳动物A/AA循环D (6) 是强大的抑制剂,表现优于奎尔塞丁.
- 哺乳动物A/AA (3) 和哺乳动物A/AB (4) 具有双重活性:抑制α-葡萄糖酶和增强葡萄糖吸收.
结论:
- 梅苏亚铁叶是有力的α-葡萄糖酶抑制剂的丰富来源.
- 化合物8和6作为开发新型糖尿病治疗的化合物具有前景.
- 双重作用化合物3和4突出显示了开发多向抗糖尿病药物的潜力.
更多相关视频
09:21Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.
Published on: February 15, 2019
10.5K
14:39Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
Published on: April 22, 2022
3.8K
相关概念视频
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
148
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
148
01:23Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165